Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avenciguat for Portal Hypertension in Decompensated Cirrhosis
NCT06082843Phase 2Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2024
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in Portal Hypertension (PH) comparing Placebo with Avenciguat (2 arms). Primary endpoint: Percentage Change in Hepatic Venous Pressure Gradient (HVPG) From Baseline at 8 weeks. Started Jan 2024; status: terminated.
02
Drugs
avenciguat
03
Conditions
Portal Hypertension (PH)
Beyond the preview
Go deeper on NCT06082843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06082843.